Literature DB >> 7460861

Effects of domperidone on serum prolactin levels in human beings.

T Fujino, H Kato, S Yamashita, S Aramaki, H Morioka, M Koresawa, F Miyauchi, H Toyoshima, T Torigoe.   

Abstract

Effects of domperidone, a dopaminergic antagonist, on serum prolactin levels were studied in 6 normal men and 6 normal cyclic women at the different phases of their menstrual cycles (i.e., the follicular, the preovulatory and the luteal phases). Domperidone (10 mg, i.v.) caused significant increases in serum prolactin in all cases within 15 min after the injection. The prolactin response was significantly (p < 0.01) higher in women than in men, and there was no significant difference in the prolactin responses among the three phases of the menstrual cycles. These results indicate that domperidone may be an effective stimulator of serum prolactin secretion in human beings.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7460861     DOI: 10.1507/endocrj1954.27.521

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  8 in total

1.  Domperidone use and risk of primary liver cancer in the Clinical Practice Research Datalink.

Authors:  Jake E Thistle; Jessica L Petrick; Baiyu Yang; Marie C Bradley; Barry I Graubard; Katherine A McGlynn
Journal:  Cancer Epidemiol       Date:  2018-07-06       Impact factor: 2.984

2.  Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child.

Authors:  Luc M Hondeghem; Noël H Logghe
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

Review 3.  Current advancements in promoting remyelination in multiple sclerosis.

Authors:  David Kremer; Rainer Akkermann; Patrick Küry; Ranjan Dutta
Journal:  Mult Scler       Date:  2018-10-01       Impact factor: 6.312

Review 4.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 5.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

6.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

7.  Etiological Profile of Galactorrhoea.

Authors:  Sridevi Atluri; Vijaya Sarathi; Amit Goel; Rakesh Boppana; C Shivaprasad
Journal:  Indian J Endocrinol Metab       Date:  2018 Jul-Aug

Review 8.  The Current Challenges for Drug Discovery in CNS Remyelination.

Authors:  Sonia Balestri; Alice Del Giovane; Carola Sposato; Marta Ferrarelli; Antonella Ragnini-Wilson
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.